Article Information
PubMed
Published By
History
- Received September 20, 2022
- Revision received December 5, 2022
- Accepted December 30, 2022
- Published online January 31, 2023.
Copyright & Usage
Copyright © 2023 Iseppon et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Author Information
- 1Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London WC1E 6BT, United Kingdom
- 2Discovery UK, Neuroscience, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB21 6GH, United Kingdom
- Correspondence should be addressed to John N. Wood at j.wood{at}ucl.ac.uk.
Author contributions
Author contributions: F.I., J.E.L., and J.N.W. designed research; F.I. and A.P.L. performed research; J.E.L. contributed unpublished reagents/analytic tools; F.I. analyzed data; F.I. and J.N.W. wrote the paper.
Disclosures
The authors declare no competing financial interests.
This work was supported by the AstraZeneca Grant 543105 (to F.I., J.E.L., and J.N.W.), the Wellcome Grant 200183/Z/15/Z (to J.N.W.), the Versus Arthritis Grant 548403 (to A.P.L., F.I., and J.N.W.), and Cancer Research UK Grant 185341 (to J.N.W.).
Funding
astra zeneca
543105Wellcome
200183/Z/15/ZVersus Arthritis
548403Cancer Research UK (CRUK)
185341
Other Version
- You are viewing the most recent version of this article.
- previous version (January 31, 2023).
Article usage
In this issue
Pregabalin Silences Oxaliplatin-Activated Sensory Neurons to Relieve Cold Allodynia
